AAAAAA

   
Results: 1-25 | 26-28
Results: 1-25/28
Fatal disseminated adenoviral infection associated with thrombotic thrombocytopenic purpura after allogeneic bone marrow transplantation
Authors: Fassas, ABT Buddharaju, LN Rapoport, A Cottler-Fox, M Drachenberg, C Meisenberg, B Tricot, G
Citation: Abt. Fassas et al., Fatal disseminated adenoviral infection associated with thrombotic thrombocytopenic purpura after allogeneic bone marrow transplantation, LEUK LYMPH, 42(4), 2001, pp. 801
Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy
Authors: Fassas, A Gojo, I Rapoport, A Cottler-Fox, M Meisenberg, B Papadimitriou, JC Tricot, G
Citation: A. Fassas et al., Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy, BONE MAR TR, 28(4), 2001, pp. 399-403
Thalidomide in the management of multiple myeloma
Authors: Barlogie, B Tricot, G Anaissie, E
Citation: B. Barlogie et al., Thalidomide in the management of multiple myeloma, SEMIN ONCOL, 28(6), 2001, pp. 577-582
Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma
Authors: Fassas, A Tricot, G
Citation: A. Fassas et G. Tricot, Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma, SEM HEMATOL, 38(3), 2001, pp. 231-242
Thalidomide in the management of multiple myeloma
Authors: Barlogie, B Zangari, M Spencer, T Fassas, A Anaissie, E Badros, A Cromer, J Tricot, G
Citation: B. Barlogie et al., Thalidomide in the management of multiple myeloma, SEM HEMATOL, 38(3), 2001, pp. 250-259
Results of autologous stem cell transplant in multiple myeloma patients with renal failure
Authors: Badros, A Barlogie, B Siegel, E Roberts, J Langmaid, C Zangari, M Desikan, R Shaver, MJ Fassas, A McConnell, S Muwalla, F Barri, Y Anaissie, E Munshi, N Tricot, G
Citation: A. Badros et al., Results of autologous stem cell transplant in multiple myeloma patients with renal failure, BR J HAEM, 114(4), 2001, pp. 822-829
Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years
Authors: Badros, A Barlogie, B Siegel, E Morris, C Desikan, R Zangari, M Fassas, A Anaissie, E Munshi, N Tricot, G
Citation: A. Badros et al., Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years, BR J HAEM, 114(3), 2001, pp. 600-607
Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma
Authors: Sawyer, JR Lukacs, JL Thomas, EL Swanson, CM Goosen, LS Sammartino, G Gilliland, JC Munshi, NC Tricot, G Shaughnessy, JD Barlogie, B
Citation: Jr. Sawyer et al., Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma, BR J HAEM, 112(1), 2001, pp. 167-174
Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma
Authors: Fassas, ABT Bolanos-Meade, J Buddharaju, LN Rapoport, A Cottler-Fox, M Chen, T Lovchik, JC Cross, A Tricot, G
Citation: Abt. Fassas et al., Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma, BR J HAEM, 112(1), 2001, pp. 237-241
Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone
Authors: Desikan, KR Tricot, G Munshi, NC Anaissie, E Spoon, D Fassas, A Toor, A Zangari, M Badros, A Morris, C Vesole, DH Siegel, D Jagannath, S Barlogie, B
Citation: Kr. Desikan et al., Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone, BR J HAEM, 112(1), 2001, pp. 242-247
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
Authors: Zangari, M Anaissie, E Barlogie, B Badros, A Desikan, R Gopal, AV Morris, C Toor, A Siegel, E Fink, L Tricot, G
Citation: M. Zangari et al., Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy, BLOOD, 98(5), 2001, pp. 1614-1615
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions (vol 97, pg 2574, 2001)
Authors: Badros, A Barlogie, B Morris, C Desikan, R Martin, SR Munshi, N Zangari, M Mehta, J Toor, A CottlerFox, M Fassas, A Aniassie, E Schichman, S Tricot, G
Citation: A. Badros et al., High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions (vol 97, pg 2574, 2001), BLOOD, 98(2), 2001, pp. 271-271
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 studyof 169 patients
Authors: Barlogie, B Desikan, R Eddlemon, P Spencer, T Zeldis, J Munshi, N Badros, A Zangari, M Anaissie, E Epstein, J Shaughnessy, J Ayers, D Spoon, D Tricot, G
Citation: B. Barlogie et al., Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 studyof 169 patients, BLOOD, 98(2), 2001, pp. 492-494
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
Authors: Badros, A Barlogie, B Morris, C Desikan, R Martin, SR Munshi, N Zangari, M Toor, A Cottler-Fox, M Fassas, A Aniassie, E Schichman, S Tricot, G
Citation: A. Badros et al., High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions, BLOOD, 97(9), 2001, pp. 2574-2579
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone
Authors: Desikan, KR Tricot, G Dhodapkar, M Fassas, A Siegel, D Vesole, DH Jagannath, S Singhal, S Mehta, J Spoon, D Anaissie, E Barlogie, B Munshi, N
Citation: Kr. Desikan et al., Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone, BONE MAR TR, 25(5), 2000, pp. 483-487
New insights into role of microenvironment in multiple myeloma
Authors: Tricot, G
Citation: G. Tricot, New insights into role of microenvironment in multiple myeloma, LANCET, 355(9200), 2000, pp. 248-250
Encouraging preliminary results in 12 patients with high-risk haematological malignancies by omitting graft-versus-host disease prophylaxis after allogeneic transplantation
Authors: Fassas, ABT Rapoport, AP Cottler-Fox, M Chen, T Tricot, G
Citation: Abt. Fassas et al., Encouraging preliminary results in 12 patients with high-risk haematological malignancies by omitting graft-versus-host disease prophylaxis after allogeneic transplantation, BR J HAEM, 111(2), 2000, pp. 662-667
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH
Authors: Shaughnessy, J Tian, E Sawyer, J Bumm, K Landes, R Badros, A Morris, C Tricot, G Epstein, J Barlogie, B
Citation: J. Shaughnessy et al., High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH, BLOOD, 96(4), 2000, pp. 1505-1511
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
Authors: Desikan, R Barlogie, D Sawyer, J Ayers, D Tricot, G Badros, A Zangari, M Munshi, NC Anaissle, E Spoon, D Siegel, D Jagannath, S Vesole, D Epstein, J Shaughnessy, J Fassas, A Lim, S Roberson, P Crowley, J
Citation: R. Desikan et al., Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities, BLOOD, 95(12), 2000, pp. 4008-4010
Stem cell factor
Authors: Lacerna, L Sheridan, WP Basser, R Begley, CG Crawford, J Demetri, G Moskowitz, CH Tricot, G Weaver, A Glaspy, JA
Citation: L. Lacerna et al., Stem cell factor, HEMATOPOIETIC STEM CELL TRANSPLANTION, 2000, pp. 31-46
Stem cell transplantation for multiple myeloma - 10 years later
Authors: Siegel, DS Lim, SH Tricot, G Desikan, KR Fassas, A Mehta, J Singhal, S Anaissie, E Jagannath, S Barlogie, B
Citation: Ds. Siegel et al., Stem cell transplantation for multiple myeloma - 10 years later, HEMATOPOIETIC STEM CELL TRANSPLANTION, 2000, pp. 499-516
Lymphomatoid granulomatosis following autologous stem cell transplantation
Authors: Fassas, A Jagannath, S Desikan, KR Shah, HR Shaver, R Waldron, J Munshi, NC Barlogie, B Tricot, G
Citation: A. Fassas et al., Lymphomatoid granulomatosis following autologous stem cell transplantation, BONE MAR TR, 23(1), 1999, pp. 79-81
Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy
Authors: Berlyn, KA Ponniah, S Stass, SA Malone, JG Hamlin-Green, G Lim, JK Cottler-Fox, M Tricot, G Alexander, RB Mann, DL Malone, RW
Citation: Ka. Berlyn et al., Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy, J BIOTECH, 73(2-3), 1999, pp. 155-179
Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma
Authors: Fassas, ABT Desikan, KR Siegel, D Golper, TA Munshi, NC Barlogie, B Tricot, G
Citation: Abt. Fassas et al., Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma, BR J HAEM, 105(4), 1999, pp. 938-941
High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia
Authors: Desikan, R Dhodapkar, M Siegel, D Fassas, A Singh, J Singhal, S Mehta, J Vesole, D Tricot, G Jagannath, S Anaissie, E Barlogie, B Munshi, NC
Citation: R. Desikan et al., High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia, BR J HAEM, 105(4), 1999, pp. 993-996
Risultati: 1-25 | 26-28